Topical Cannabis Formulations with High THC and CBD Concentrations
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current topical formulations derived from Cannabis lack high concentrations of tetrahydrocannabinol (THC) and cannabidiol (CBD), which are necessary to exploit their full pharmacological potential in treating dermatological diseases, as they typically adhere to legal limits that restrict therapeutic efficacy.
Innovation Solution
Development of topical formulations with THC and CBD concentrations exceeding 2 milligrams per kilogram, combined with additional active ingredients such as hydrocortisone, antibiotics, antiseptics, and analgesics, in various forms like lotions, creams, and ointments, to enhance therapeutic benefits.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If topical formulations adhere to legal limits for THC and CBD concentrations, then regulatory compliance is maintained, but therapeutic efficacy is insufficient
Solution Approach 1:
The patent changes the concentration parameter of THC and CBD from trace amounts (below detection limit or at legal limits) to high concentrations (exceeding 2 mg/kg, with THC specifically at >2 mg/kg). This parameter change enables the formulation to achieve therapeutic efficacy while maintaining regulatory compliance through the specific definition of Cannabis derived botanical drug product
Solution Approach 2:
The patent applies local quality by creating formulations with non-uniform cannabinoid distribution or specific localized concentrations of THC and CBD in different portions of the topical formulation, allowing different therapeutic effects in different areas of application while maintaining overall compliance
2Ease of manufacture
If topical formulations use only trace amounts of cannabinoids as in conventional hemp oil, then legal limits are met, but pharmacological activity is insufficient for treating dermatological diseases
Solution Approach 1:
The patent creates composite topical formulations that combine Cannabis derived botanical drug product with other active ingredients such as hydrocortisone, antibiotics, antiseptics, and analgesics. This composite approach allows the formulation to achieve enhanced therapeutic efficacy for dermatological conditions while maintaining regulatory compliance through the specific definition and concentration thresholds established
3Quantity of substance
If THC concentration is increased above detection limit to achieve therapeutic effect, then dermatological treatment efficacy improves, but psychotropic effects may occur
Solution Approach 1:
The patent changes the THC concentration parameter to a specific range (>2 mg/kg but controlled) and combines it with CBD and other active ingredients to achieve therapeutic efficacy while minimizing psychotropic effects through the synergistic interaction and controlled dosing
Solution Approach 2:
The patent uses CBD and other active ingredients as intermediaries or moderators that can mitigate the psychotropic effects of THC while preserving its therapeutic benefits for dermatological conditions. The combination acts as a balanced system where each component modulates the effects of the others
Data Source
AI summary
A topical formulation comprising a Cannabis derived botanical drug product, wherein the concentration of each, cannabidiol and tetrahydrocannabinol, in the topical formulation is greater than 2 milligrams per kilogram.